Barclays PLC Acquires 255,750 Shares of iShares Biotechnology ETF $IBB

Posted by ABMN Staff on Jun 16th, 2026

Barclays PLC grew its holdings in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 61.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 671,941 shares of the financial services provider’s stock after acquiring an additional 255,750 shares during the quarter. Barclays PLC owned 1.38% of iShares Biotechnology ETF worth $113,403,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Basepoint Wealth LLC bought a new stake in shares of iShares Biotechnology ETF in the fourth quarter worth about $26,000. Cary Street Partners Financial LLC bought a new position in shares of iShares Biotechnology ETF during the fourth quarter worth about $29,000. Darwin Wealth Management LLC bought a new position in shares of iShares Biotechnology ETF during the second quarter worth about $25,000. Cornerstone Planning Group LLC bought a new position in shares of iShares Biotechnology ETF during the fourth quarter worth about $35,000. Finally, Copia Wealth Management bought a new position in shares of iShares Biotechnology ETF during the fourth quarter worth about $34,000. 62.45% of the stock is currently owned by institutional investors.

iShares Biotechnology ETF Trading Up 0.9%

NASDAQ IBB opened at $172.17 on Tuesday. iShares Biotechnology ETF has a 12-month low of $123.61 and a 12-month high of $179.64. The firm’s 50 day moving average is $170.34 and its 200-day moving average is $170.66.

iShares Biotechnology ETF Cuts Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 18th. Investors of record on Monday, June 15th will be issued a dividend of $0.0238 per share. The ex-dividend date is Monday, June 15th. This represents a $0.10 annualized dividend and a yield of 0.1%.

About iShares Biotechnology ETF

(Free Report)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.